Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

FED

Sponsor class

Conditions

Meningococcal Infection, Group B

Interventions

BIOLOGICAL: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
BIOLOGICAL: 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
BIOLOGICAL: 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
BIOLOGICAL: 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine

Sponsor

U.S. Army Medical Research and Development Command